Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tscan Therapeutics Inc (NQ: TCRX )

5.740 -0.050 (-0.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 90,555
Open 5.790
Bid (Size) 5.730 (3)
Ask (Size) 5.740 (40)
Prev. Close 5.790
Today's Range 5.605 - 5.840
52wk Range 1.970 - 9.690
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
Via Benzinga
TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024
TCRX stock results show that TScan Therapeutics met analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+0.53%
+0.53%
1 Month
-21.90%
-21.90%
3 Month
-36.08%
-36.08%
6 Month
-15.34%
-15.34%
1 Year
+180.00%
+180.00%

More News

Read More
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Updates to its Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
The Analyst Landscape: 7 Takes On TScan Therapeutics
Via Benzinga
Key Takeaways From TScan Therapeutics Analyst Ratings
Via Benzinga
Unveiling 4 Analyst Insights On TScan Therapeutics
Via Benzinga
TScan Therapeutics: Q4 Earnings Insights
Via Benzinga
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
From TScan Therapeutics, Inc.
Via GlobeNewswire
TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Closing of Upsized Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
Via InvestorPlace
TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.